Das hepatozelluläre Karzinom (HCC): Leitliniengerechte interventionelle Therapieoptionen
Prof. Dr. Thomas J. Vogl
At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us. For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in. We have worked tirelessly to bring forward medicines for life-threatening diseases. Through bold and transformative science, we’re driving innovation that has the potential to become the next generation of life-changing medicines. Our ambition is evident in our mission. Because the impossible is not impossible. It’s what’s next.
|Fr. Silvia Dambacher||Fr. Andra Kuske|
|Mail: firstname.lastname@example.org||Mail: email@example.com|